Welcome to our dedicated page for CALITHERA BIOSCIENCES news (Ticker: CALA), a resource for investors and traders seeking the latest updates and insights on CALITHERA BIOSCIENCES stock.
Calithera Biosciences Inc. (CALA) is a pioneering biopharmaceutical company dedicated to the discovery and development of first-in-class small molecule drugs aimed at slowing tumor growth. Their approach focuses on controlling key metabolic pathways in both tumor and immune cells, targeting the distinct metabolic requirements of these cells to impede cancer proliferation.
Calithera leverages the promising fields of tumor metabolism and tumor immunology to create new, innovative cancer therapies. Recent clinical successes highlight the potential of their investigational medicines to slow abnormal cell growth and offer fundamentally new treatment options for cancer patients.
Currently, Calithera's lead candidate is in Phase 2 trials for patients with renal cell carcinoma and triple negative breast cancer. These trials are crucial given the urgent need for new treatments in these solid tumors.
Calithera also engages in strategic partnerships to bolster its research and development efforts. Their onco-metabolism approach aims to bring a fresh perspective to cancer treatment by exploiting the unique metabolic needs of cancer cells versus cancer-fighting immune cells.
For more information, latest updates, and significant news regarding Calithera Biosciences Inc., visit their official webpage or contact them directly.
Calithera Biosciences (CALA) will release its fourth quarter and full year 2021 financial results on March 31, 2022. A conference call will follow at 2:00 PM PT to discuss the results and corporate highlights. Investors can access the call through the company website or by phone. Calithera focuses on precision oncology, developing therapies targeting genetic vulnerabilities in cancer cells, particularly for aggressive cancers with limited treatment options.
Calithera Biosciences announced the first data from its preclinical synthetic lethality program involving novel VPS4A inhibitors at the AACR 2022 Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The research highlights that VPS4A inhibition leads to significant cancer cell death in VPS4B-deleted tumor cell lines. This discovery targets a range of cancers, including colorectal and pancreatic cancers, indicating a promising approach for patients with high unmet medical needs.
Calithera Biosciences (Nasdaq: CALA) announced that its founder and CEO, Susan Molineaux, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 p.m. ET. The event will be available for replay on the company’s website for 30 days. Calithera focuses on developing precision oncology therapies targeting genetic vulnerabilities in cancer cells, aiming to improve treatment for patients with aggressive hematologic and solid tumor cancers.
AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced significant advancements in its development efforts. The company successfully completed an oversubscribed $80 million Series B financing, aiming to advance its lead candidate, epetraborole, for treating chronic non-tuberculous mycobacterial lung disease (NTM). This financing involved prominent investors, including RA Capital Management and BVF Partners. Additionally, two experienced members were appointed to the Board of Directors to enhance strategic capabilities.
Calithera Biosciences, a precision oncology biopharmaceutical company, announced that its founder and CEO, Susan Molineaux, will present at the H.C. Wainwright BioConnect Virtual Conference on January 10, 2022. The session will introduce the company’s latest corporate presentation, available on its website. Calithera focuses on developing targeted therapies aimed at biomarker-specific patient populations in cancer treatment. The webcast will be accessible for on-demand viewing for 30 days following the presentation.
Calithera Biosciences (Nasdaq: CALA) announced that its founder and CEO, Susan Molineaux, Ph.D., will present at the 2021 Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting November 18 at 3:00 a.m. ET on the company's website. A replay will remain accessible for 30 days. Calithera is focused on developing targeted therapies for biomarker-specific cancer patient populations, aiming to treat aggressive cancers where options are limited.
Calithera Biosciences announced its third-quarter financial results and strategic advancements on November 9, 2021. The company acquired two investigational therapies, sapanisertib and mivavotinib, enhancing its precision oncology pipeline. Cash reserves stood at $84.5 million, expected to support operations into 2023. Revenue for the quarter was $6.8 million, primarily from a milestone payment. R&D expenses dropped to $11.6 million, while G&A expenses rose to $6.3 million. The discontinuation of the telaglenastat program was also noted, citing lack of clinical benefit.
Calithera Biosciences (Nasdaq: CALA) has announced the termination of its phase 2 KEAPSAKE clinical trial due to lack of clinical benefit from telaglenastat, based on interim analysis. The study focused on patients with stage IV non-squamous non-small cell lung cancer. No significant safety differences were reported between trial groups. The company plans to redirect its efforts towards advancing targeted oncology therapies, including sapanisertib and mivavotinib, while discontinuing telaglenastat development. Estimated cost savings from this discontinuation range from $10-15 million.
Calithera Biosciences announces the promotion of Dr. Emil T. Kuriakose to Chief Medical Officer, succeeding Dr. Keith Orford, who joins the board of directors. Dr. Kuriakose has a strong background in leading clinical programs and has been with Calithera for four years. He played a significant role in the acquisition of sapanisertib and mivavotinib from Takeda Pharmaceuticals and has overseen key clinical development initiatives. This transition aims to enhance Calithera's strategy in developing targeted therapies for specific patient populations.
Calithera Biosciences (CALA) announced the release of its third quarter 2021 financial results on November 9, 2021. A conference call will follow on the same day at 2:00 PM PT to discuss these results and recent corporate developments. Investors can access the press release and live audio webcast through the company's website. Founded in South San Francisco, Calithera focuses on developing targeted therapies for cancer treatment, aiming to improve outcomes for patients with limited options.
FAQ
What is the market cap of CALITHERA BIOSCIENCES (CALA)?
What does Calithera Biosciences Inc. specialize in?
What is the primary focus of Calithera's research?
What are Calithera's lead candidates currently being tested for?
How does Calithera's onco-metabolism approach work?
What recent achievements has Calithera accomplished?
Who can I contact for more information about Calithera?
Where can I find the latest updates on Calithera?
What kind of partnerships does Calithera engage in?
Why is Calithera's research important?
What makes Calithera's therapy approach unique?
